10-Q: Sanara MedTech Reports Strong Revenue Growth

Sanara MedTech Inc. reports significant revenue growth in its surgical segment, alongside strategic investments in its new value-based wound care platform.

Summary

• Net revenue for the three months ended June 30, 2025, increased by 28% to $25.8 million, up from $20.2 million in the prior year period.
• Gross profit for the three months ended June 30, 2025, rose by 32% to $23.9 million, compared to $18.2 million in the same period last year.
• Operating loss significantly improved to $(31,348) for the three months ended June 30, 2025, from $(2,884,856) in the prior year.
• Net loss for the three months ended June 30, 2025, decreased to $(2.0) million from $(3.5) million in the prior year period.
• Segment Adjusted EBITDA for the three months ended June 30, 2025, increased to $2.7 million, up from $0.6 million in the prior year.
• For the six months ended June 30, 2025, net revenue increased by 27% to $49.3 million, compared to $38.7 million in the prior year period.
• Gross profit for the six months ended June 30, 2025, increased by 31% to $45.5 million, up from $34.8 million in the prior year period.
• Net loss for the six months ended June 30, 2025, was $(5.5) million, a slight increase from $(5.3) million in the prior year, primarily due to investments in the THP segment and higher interest expense.
• The Tissue Health Plus (THP) segment incurred a net loss of $(2.5) million for the three months and $(5.4) million for the six months ended June 30, 2025, as it is in early stages of development.
• Cash on hand increased to $17.0 million as of June 30, 2025, from $15.9 million at December 31, 2024.
• Long-term debt increased to $44.2 million as of June 30, 2025, from $30.7 million at December 31, 2024, due to additional borrowings under the CRG Term Loan.
• The company completed the CarePICS Acquisition on April 1, 2025, for $2.0 million cash consideration, assumed $1.65 million in debt, and potential earnout payments up to $20.0 million.
• An additional $12.25 million was borrowed under the CRG Term Loan on March 31, 2025, with $12.25 million remaining available for future borrowing until December 31, 2025.
• An initial cash investment of approximately €3.0 million and conversion of a €1.0 million convertible loan into 6.67% equity in Biomimetic Innovations Limited (BMI) was made on January 16, 2025, with an additional $2.4 million (€2.0 million) paid on July 1, 2025, increasing ownership to 9.678%.

Sentiment

Score: 7

Explanation: The company demonstrates strong revenue growth and improved operational efficiency in its core surgical segment. Strategic investments in the high-potential THP segment and new product lines (BMI) are positive for long-term growth, despite currently contributing to net losses and increased debt. The proactive pursuit of financial partners for THP indicates a sound strategy to de-risk this investment. Overall, the filing suggests a company executing on its growth strategy with promising underlying business performance, balanced by the costs of expansion.

Positives

• Strong net revenue growth of 28% for the quarter and 27% for the six-month period, driven by increased market penetration and geographic expansion of soft tissue repair and bone fusion products.
• Significant improvement in gross profit margins due to increased sales of soft tissue repair products and lower manufacturing costs for CellerateRX Surgical.
• Substantial reduction in operating loss and net loss for the three months ended June 30, 2025, indicating improved operational efficiency in the core Sanara Surgical segment.
• Segment Adjusted EBITDA saw a significant increase, reflecting stronger core business performance.
• Successful acquisition of CarePICS, which is expected to enhance the THP platform's technology capabilities.
• Strategic investment in Biomimetic Innovations Limited (BMI) and acquisition of exclusive U.S. marketing, sales, and distribution rights for key trauma products (OsStic and ARC).
• Maintained compliance with all debt covenants under the CRG Term Loan Agreement.
• Cash on hand increased, providing liquidity for ongoing operations and strategic initiatives.

Negatives

• Overall net loss for the six months ended June 30, 2025, increased slightly compared to the prior year, primarily due to significant investments in the developing THP segment and higher interest expense.
• The Tissue Health Plus (THP) segment is currently operating at a significant loss, with a net loss of $(5.4) million and Segment Adjusted EBITDA of $(4.1) million for the six months ended June 30, 2025, indicating it is a cash-intensive growth area.
• Long-term debt increased substantially to $44.2 million, leading to higher interest expenses.
• The THP pilot program has not yet generated any revenue, indicating it is still in very early stages of commercialization.

Risks

• Shortfalls in forecasted revenue growth.
• Ability to implement value-based wound and skin strategy through acquisitions and investments and realize anticipated benefits.
• Ability to meet future capital requirements.
• Ability to maintain compliance with debt obligations.
• Ability to develop and commercialize new products and products under development, including manufacturing, distribution, marketing, and sale.
• Ability to retain and recruit key personnel.
• Intense competition in the markets in which the company operates and its ability to compete.
• Failure of products to obtain market acceptance.
• Effect of security breaches and other disruptions.
• Ability to maintain effective internal controls over financial reporting.
• Ability to maintain and further grow clinical acceptance and adoption of products.
• Impact of competitors inventing products that are superior.
• Disruptions of, or changes in, the distribution model, consumer base, or supply of products.
• Failure of third-party assessments to demonstrate desired outcomes in proposed endpoints.
• Ability to successfully expand into value-based wound, skin, and other services.
• Ability and the ability of research and development partners to protect proprietary rights to technologies and the impact of any intellectual property infringement claims.
• Dependence on technologies and products licensed from third parties.
• Effects of current and future laws, rules, regulations, and reimbursement policies relating to labeling, marketing, and sale of products, and the planned launch of value-based services.
• Effect of defects, failures, or quality issues associated with products.

Future Outlook

The company expects to continue its investment in the Tissue Health Plus (THP) strategy, projecting a cash investment between $5.5 million and $6.5 million during the second half of 2025, with no material cash investments anticipated after year-end. Future needs for cash include funding THP, potential acquisitions, BMI milestone payments, product development, clinical studies, and debt repayment. The company believes current cash, expected cash flows, and available CRG Term Loan proceeds will be sufficient for at least the next 12 months. A formal process has been initiated to evaluate a full range of strategic alternatives for THP to maximize shareholder value.

Management Comments

• We strive to be one of the most innovative and comprehensive providers of effective surgical, wound and skin solutions and are continually seeking to expand our offerings for patients requiring treatments across the entire continuum of care in the United States.
• Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care.
• We believe that we have the ability to drive our product pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements.
• We are constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost.
• We anticipate that THP's customer contracts will have three-to-five-year terms, incorporating a mix of value-based pricing methodologies including episodic, per member per month, and fee for value pricing.
• We believe this approach is aligned with the financial goals of the payers and will help deliver outstanding clinical outcomes for the patients.
• Our vision for our comprehensive approach consists of three key sets of planned capabilities: Care Hub, Managed Services Organization (MSO) Network, and Technology Platform.
• We anticipate that our platform will leverage our technology investments and partnerships with Precision Healing Inc., Pixalere Healthcare, Inc., CarePICS, LLC and others, by leveraging modern technology including artificial intelligence and machine learning.
• We have initiated a formal process to evaluate a full range of strategic alternatives for THP, with a focus on identifying and pursuing the best path forward to maximize value for our company and its shareholders.
• We expect our future needs for cash to include the funding of our additional investment in THP, potential acquisitions, certain milestone payments related to our BMI investment, further development of our products, services and technologies pipeline, clinical studies, repayment of debt as it becomes due and for general corporate purposes.

Industry Context

The company operates in the medical technology sector, specifically targeting surgical, chronic wound, and skin markets. Its strategy to expand into value-based wound care through the THP segment aligns with broader healthcare trends emphasizing cost reduction, improved patient outcomes, and integrated care delivery models. The acquisition of CarePICS and investment in BMI reflect a focus on leveraging technology and expanding product offerings to gain market share and address unmet needs in these evolving segments. The shift to value-based care models is a significant industry trend, and the company's proactive approach positions it to capitalize on this transformation, despite the initial investment costs.

Comparison to Industry Standards

• The company's 27-28% revenue growth rate in its Sanara Surgical segment is robust and suggests strong market penetration and geographic expansion, potentially outperforming some industry peers in a mature medical device market.
• The significant improvement in gross profit margins indicates effective cost management and potentially favorable product mix within the Sanara Surgical segment, which is a positive sign for operational efficiency compared to general industry benchmarks.
• The investment in the Tissue Health Plus (THP) segment, while currently generating losses, represents a strategic move into the value-based wound care market. This is a nascent but high-potential area, and direct comparable financial results from established competitors in this exact model are limited, making a direct financial comparison challenging. However, the company's proactive entry positions it as an early mover in this evolving space.
• The CRG Term Loan's 13.25% interest rate, with a portion paid-in-kind, is relatively high, reflecting the company's growth stage and potentially higher risk profile compared to larger, more established medical technology companies with access to lower-cost capital.
• The capitalization of internal use software costs for the THP platform ($3.4 million for six months) is a common practice for technology-driven healthcare companies investing in scalable digital solutions, aligning with industry standards for software development accounting.

Corporate Governance

Legal Proceedings

• No material pending legal proceedings to which the company is a party or of which any of its property is the subject.

Related Party Transactions

• Ongoing product license agreements with Rochal Industries, LLC (BIAKS License Agreement, ABF License Agreement, Debrider License Agreement), where the company's Executive Chairman and CEO, Ronald T. Nixon, and another director are significant shareholders and/or directors.
• Consulting agreement with Ann Beal Salamone, a company director and significant shareholder/Chair of Rochal, for an annual consulting fee of $177,697.
• Transaction Advisory Services Agreement with Catalyst, a related party, for which the company incurred costs of $10,000 for the three months and $30,000 for the six months ended June 30, 2025.
• Outstanding related party receivables totaling $9,081 as of June 30, 2025.
• Outstanding related party payables totaling $32,355 as of June 30, 2025.

Stakeholder Impact

• **Shareholders**: Potential for long-term value creation through strategic investments in THP and new product lines, but also exposure to increased debt and current losses from the THP segment. The evaluation of strategic alternatives for THP aims to maximize shareholder value.
• **Employees**: Continued investment in R&D and the THP platform suggests ongoing job opportunities and development. Share-based compensation plans are in place to incentivize employees.
• **Customers**: Expansion of product offerings (e.g., through BMI acquisition) and the development of the THP value-based wound care program aim to provide better clinical outcomes and potentially lower costs.
• **Suppliers**: Continued growth in the Sanara Surgical segment and development of new products will likely maintain or increase demand for raw materials and manufacturing services.
• **Creditors**: Increased long-term debt means higher interest payments, but the company is currently in compliance with debt covenants and has available liquidity, which is positive for creditors.

Next Steps

• Continue investment in the Tissue Health Plus (THP) strategy, with projected cash investment of $5.5 million to $6.5 million in the second half of 2025.
• Seek financial partners to invest in the execution of the THP strategy.
• Further develop products, services, and technologies pipeline.
• Conduct clinical studies for new products.
• Repay debt as it becomes due.
• Utilize the remaining $12.25 million available for future borrowing under the CRG Term Loan for permitted acquisition opportunities and general working capital.
• Achieve certain development, clinical, and regulatory milestones for BMI to trigger additional capital contributions and equity issuance.
• Negotiate applicable percentage of net sales for ARC under the BMI License Agreement at a future date.
• Continue to coordinate delivery of community and home-based wound care for managed patients through THP programs.
• Integrate science and evidence-based medicine protocols to standardize wound prevention and treatment within THP programs.
• Evaluate a full range of strategic alternatives for THP to maximize value for the company and its shareholders.

Key Dates

Recommendation

Sanara MedTech Inc. presents a mixed but strategically focused financial picture. The core Sanara Surgical segment demonstrates robust revenue growth (28% quarterly, 27% six-month) and improved gross margins, indicating strong operational performance. This positive momentum is partially offset by the significant investment in the Tissue Health Plus (THP) segment, which is currently a drag on net profitability and cash flow, leading to an increased six-month net loss and higher debt. However, the company is actively pursuing external financial partners for THP, which could de-risk this long-term growth initiative. The recent acquisitions (CarePICS) and strategic investments (BMI) are forward-looking moves to expand market reach and product offerings. Given the strong performance of the core business, the strategic rationale behind THP, and the ongoing efforts to secure external funding for the new segment, a 'hold' recommendation is appropriate. Investors should monitor the progress of the THP segment and its ability to attract external capital, as well as the impact of increased debt on future profitability. The stock holds potential for long-term growth, but the current investment phase introduces near-term uncertainties.

Keywords

Medical Technology, Wound Care, Surgical Products, Soft Tissue Repair, Bone Fusion, Value-Based Care, Healthcare, SEC Filing, 10-Q, Sanara MedTech, SMTI, Biologics, Collagen, Biomimetic Innovations, CarePICS